Pfizer could be just a few months away from getting FDA approval for its JAK1 inhibitor abrocitinib in atopic dermatitis, a drug that CEO Albert Bourla believes hasn’t been given the credit it ...

Abrocitinib is under clinical development by Pfizer and currently in Phase II for Dermatological Disorders. According to GlobalData, Phase II drugs for Dermatological Disorders have a 20% phase ...

Other analysts think strong competition could come from Pfizer’s oral JAK1 inhibitor abrocitinib, which this week hit the mark in moderate-to-severe atopic dermatitis in adolescents in the JADE ...

With Staquis and Cibinqo, Pfizer is empowering patients with effective options ... Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with ...

In a similar manner, Spain's Ministry of Health (MoH) proposed that Pfizer's atopic dermatitis treatment Cibinqo (abrocitinib) is equivalent to Almirall's Ebglyss. This news was a surprise to ...

In a similar manner, Spain’s Ministry of Health (MoH) proposed that Pfizer’s atopic dermatitis treatment Cibinqo (abrocitinib) is equivalent to Almirall’s Ebglyss. This news was a surprise to Almirall ...

Studies examining real-world biomarkers over time have significant implications, and follow-up rates are 70% for dupilumab; 21% for tralokinumab; and 19%, 35%, and 19% for baricitinib, upadacitinib, ...

NEW YORK, Feb 3 (Reuters) - Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer (PFE.N ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

However, at least two conditions listed as adverse events also appeared in Pfizer's 2024 list of genuine side effects. In January 2025, Snopes readers asked us about the authenticity of a long ...